Funds Still Love Meta Platforms — Should Retail Add on Dips?
Funds remain heavily invested in Meta Platforms as AI boosts ads and cash flow — but at today’s price, patience may still pay off.
John Rogers’ Ariel Investments Loves Madison Square Garden Entertainment: Should You?
MSGE owns some of the world’s most iconic entertainment venues. Demand is strong — but leverage and price argue for patience.
Nvidia Is a Top-Five Stock Held by Hedge Funds: Should You Buy — or Even Hold?
Nvidia is the crown jewel of AI and a top hedge-fund holding. The company is stellar — but is the stock still worth buying in 2026?
Hedge Funds Like Royalty Pharma: Should Retail Wear the Crown?
Royalty Pharma isn’t a biotech moonshot — it’s a cash-collecting royalty king. Hedge funds are buying, buybacks are flowing, and dividends keep compounding. 👑💊
Hedge Funds Miller Value and Värde Partners Love Nabors Industries’ Cheap Shares, Deleveraging, and Saudi Aramco JV
Hedge funds are circling Nabors Industries — and not by accident. With aggressive deleveraging, a Saudi Aramco joint venture, and valuation metrics that still scream skepticism, NBR may be one of energy’s most misunderstood value plays.
Buffett Steps Down as CEO — Should You Step Away from Berkshire?
Buffett steps aside as CEO. The cash pile is massive. The machine still hums. Should long-term investors stay the course with Berkshire Hathaway?
Michael Burry Has 38% of His Portfolio in Lululemon: Time To Wear The Pants?
Michael Burry just made Lululemon a top portfolio holding. With valuation down, buybacks up, and shorts watching — is it time to wear the pants?
Insiders Are Buying Under Armour: Strong Suit or Skip the Knight-Mare?
Under Armour trades over 90% below its all-time high—but insiders are buying aggressively. Is this a rare turnaround opportunity or a classic value trap? Let’s break it down.
Baker Bros Are Bullish — Can Kodiak Kill the Bears?
When the sharpest biotech investors on the planet deploy $60 million, it’s worth paying attention. Kodiak Sciences is a high-risk, high-reward retinal biotech with late-stage trials, real institutional backing, and binary outcomes ahead. Fun, factual, and unapologetically speculative.
Kenvue Director Jeff Smith of Starboard Value Buys Shares of KVUE; He Must Love Kimberly-Clark. Should You?
A $111 million insider buy. Nearly 100% institutional ownership. A blockbuster merger with Kimberly-Clark. Kenvue suddenly looks boring… in a very interesting way.